The possible cost effectiveness of peripheral blood stem cell mobilization with clophosphamide and the late addition of G-CSF.
10.3346/jkms.2000.15.1.49
- Author:
Young Joo MIN
1
;
Sang We KIM
;
Cheolwon SUH
;
Jinny PARK
;
Hyo Jung KIM
;
Jeong Gyoon KIM
;
Tae Won KIM
;
Je Hwan LEE
;
Sung Bae KIM
;
Kyoo Hyung LEE
;
Jung Shin LEE
;
Woo Kun KIM
;
Sang Hee KIM
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Clinical Trial ; Comparative Study ; Randomized Controlled Trial
- Keywords:
Stem Cells;
CD34 Antigen;
Hematopietic Stem Cell Transplantation;
Granulocyte Colony-Stimulation Factor
- MeSH:
Adult;
Aged;
Antigens, CD34/metabolism;
Antigens, CD34/immunology;
Antineoplastic Agents, Alkylating/therapeutic use*;
Antineoplastic Agents, Alkylating/adverse effects;
Breast Neoplasms/therapy;
Comparative Study;
Cost-Benefit Analysis;
Cyclophosphamide/therapeutic use*;
Cyclophosphamide/adverse effects;
Drug Administration Schedule;
Female;
Graft Survival;
Granulocyte Colony-Stimulating Factor/therapeutic use*;
Granulocyte Colony-Stimulating Factor/adverse effects;
Hematopoietic Stem Cell Mobilization/methods*;
Hematopoietic Stem Cell Mobilization/economics*;
Hematopoietic Stem Cell Mobilization/adverse effects;
Hematopoietic Stem Cell Transplantation;
Hematopoietic Stem Cells/metabolism;
Hematopoietic Stem Cells/immunology;
Human;
Lymphoma, Non-Hodgkin/therapy;
Male;
Middle Age;
Multiple Myeloma/therapy;
Sarcoma, Ewing's/therapy
- From:Journal of Korean Medical Science
2000;15(1):49-52
- CountryRepublic of Korea
- Language:English
-
Abstract:
The purpose of this study was to develop a cost-effective protocol for the mobilization of peripheral blood stem cells (PBSC) in patients with malignancy. Thirty consecutive patients were randomized to mobilize PBSC with the late addition of a standard 250 microg dose of G-CSF (Neutrogen) from day 8 or early addition of the same dose of G-CSF from day 2, following cyclophosphamide (CY) 4 g/m2. The median yield of CD34+ cells from evaluated patients was 7.87 x 10(6)/kg (range, 2.06-27.25), collected in a median of four apheresis (range, 2-9). Target CD34 + cell doses > or = 2.0 x 10(6)/kg were achieved in all patients able to be evaluated. There were no statistically significant differences in CD34+ cell yields or toxicities. Overall engraftment occurred with median days to neutrophils > or = 0.5 x 10(9)/L or platelets > 20 x 10(9)/L of 11 and 17 days, respectively. However, the duration of G-CSF administration was markedly shorter in the late use of G-CSF group than in the early use of G-CSF group, with a median of 9 days compared with 15 days (p>0.001). PBSC harvesting after priming with CY plus delayed use of G-CSF made it a safe and cost-effective procedure.
